NorthLinks Bio
St Andrews, GB · 1 known investors
Find your way into NorthLinks Bio
266 people in our graph share verified history with the NorthLinks Bio team — schools, employers, funds. One of them is your warm intro.
Scott Billerunlockedknows Fanny Cavalié · together at Foghorn Therapeutics, Inc (overlapped)
×2knows the team · via HEC Paris
×9knows the team · via Cornell Johnson Graduate School of Management
NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17, an intranasal antiviral designed to prevent respiratory virus infections by blocking viral entry at the nasal epithelium. The company targets broad protection against multiple respiratory viruses through a strain-independent mechanism.
Founders & leadership
FC
Fanny CavaliéinChief Executive OfficerShe has over 20 years of experience in biotech and healthcare across multiple therapeutic areas, with background in building teams and operationalizing strategies from discovery through commercialization.
Investors · 1
In the news
Frequently asked questions
- What does NorthLinks Bio do?
- NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17, an intranasal antiviral designed to prevent respiratory virus infections by blocking viral entry at the nasal epithelium. The company targets broad protection against multiple respiratory viruses through a strain-independent mechanism.
- Who are NorthLinks Bio's investors?
- NorthLinks Bio's investors include RA Capital.
- Where is NorthLinks Bio headquartered?
- NorthLinks Bio is headquartered in St Andrews, GB.